المؤلفون: Sibley, CR, Seow, Y, Saayman, S, Dijkstra, KK, El Andaloussi, S, Weinberg, MS, Wood, MJA

المصدر: Nucleic acids research. 40(1):438-448

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:123900213

المؤلفون: Enfield KSS; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Colliver E; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Lee C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Magness A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Moore DA; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Department of Cellular Pathology, University College London Hospitals, London, United Kingdom., Sivakumar M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Grigoriadis K; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Pich O; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Karasaki T; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, United Kingdom., Hobson PS; Flow Cytometry, The Francis Crick Institute, London, United Kingdom., Levi D; Flow Cytometry, The Francis Crick Institute, London, United Kingdom., Veeriah S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Puttick C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Nye EL; Experimental Histopathology, The Francis Crick Institute, London, United Kingdom., Green M; Experimental Histopathology, The Francis Crick Institute, London, United Kingdom., Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Shimato M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Akarca AU; Department of Cellular Pathology, University College London Hospitals, London, United Kingdom., Marafioti T; Department of Cellular Pathology, University College London Hospitals, London, United Kingdom., Salgado R; Department of Pathology, ZAS Hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Hackshaw A; Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, United Kingdom.; Department of Oncology, University College London Hospitals, London, United Kingdom., van Maldegem F; Oncogene Biology Laboratory, The Francis Crick Institute, London, United Kingdom., McGranahan N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Glass B; PathAI, Inc., Boston, Massachusetts., Pulaski H; PathAI, Inc., Boston, Massachusetts., Walk E; PathAI, Inc., Boston, Massachusetts., Reading JL; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Pre-cancer Immunology Laboratory, University College London Cancer Institute, London, United Kingdom.; Immune Regulation and Tumour Immunotherapy Group, Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, United Kingdom., Quezada SA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Immune Regulation and Tumour Immunotherapy Group, Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, United Kingdom., Hiley CT; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom., Downward J; Oncogene Biology Laboratory, The Francis Crick Institute, London, United Kingdom., Sahai E; Tumour Cell Biology Laboratory, The Francis Crick Institute, London, United Kingdom., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.; Department of Oncology, University College London Hospitals, London, United Kingdom., Angelova M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.

مؤلفون مشاركون: TRACERx consortium

المصدر: Cancer discovery [Cancer Discov] 2024 Jun 03; Vol. 14 (6), pp. 1018-1047.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: Lung Neoplasms*/immunology , Lung Neoplasms*/pathology , Lung Neoplasms*/genetics , Tumor Microenvironment*/immunology, Humans ; T-Lymphocytes/immunology ; Myeloid Cells/immunology ; Female ; Male ; Immune Evasion

المؤلفون: Deben C; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium. christophe.deben@uantwerpen.be., Boullosa LF; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Fortes FR; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., De La Hoz EC; Industrial Vision Lab, University of Antwerp, Wilrijk, Belgium., Le Compte M; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Seghers S; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Peeters M; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Vanlanduit S; Industrial Vision Lab, University of Antwerp, Wilrijk, Belgium., Lin A; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Plasma Lab for Applications in Sustainability and Medicine ANTwerp (PLASMANT), University of Antwerp, Wilrijk, Belgium., Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Van Schil P; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium., Hendriks JMH; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium., Prenen H; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Oncology, Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Antwerp, Belgium., Roeyen G; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Hepatobiliary Transplantation and Endocrine Surgery, University Hospital Antwerp (UZA), Edegem, Belgium., Lardon F; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium., Smits E; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.

المصدر: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Mar 22; Vol. 43 (1), pp. 88. Date of Electronic Publication: 2024 Mar 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/genetics , Pancreatic Neoplasms*/pathology , Carcinoma, Pancreatic Ductal*/drug therapy , Adenocarcinoma*/drug therapy , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use , Carbonic Anhydrases*, Humans ; Auranofin/pharmacology ; Auranofin/therapeutic use ; Proto-Oncogene Proteins c-akt/metabolism ; Drug Repositioning ; Lung/pathology ; Biomarkers ; Organoids/metabolism

المؤلفون: Hughes T; Wellcome Trust/CRUK Gurdon Institute and Department Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom., Rawlins EL; Wellcome Trust/CRUK Gurdon Institute and Department Physiology, Development and Neuroscience, University of Cambridge, Cambridge, United Kingdom., Hynds RE; Epithelial Cell Biology in ENT Research (EpiCENTR) Group, Developmental Biology and Cancer Department, Great Ormond Street UCL Institute of Child Health, University College London, London, United Kingdom.; CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, United Kingdom.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.

المصدر: Frontiers in pharmacology [Front Pharmacol] 2023 Jan 13; Vol. 13, pp. 1083017. Date of Electronic Publication: 2023 Jan 13 (Print Publication: 2022).

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE

المؤلفون: Picco G; Wellcome Sanger Institute, Cambridge, United Kingdom., Cattaneo CM; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., van Vliet EJ; Wellcome Sanger Institute, Cambridge, United Kingdom., Crisafulli G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Rospo G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Consonni S; Wellcome Sanger Institute, Cambridge, United Kingdom., Vieira SF; Wellcome Sanger Institute, Cambridge, United Kingdom., Rodríguez IS; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Cancelliere C; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy., Banerjee R; Wellcome Sanger Institute, Cambridge, United Kingdom., Schipper LJ; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Oddo D; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Cinatl J; Institute for Medical Virology, Goethe-University, Frankfurt am Main, Germany., Michaelis M; School of Biosciences, University of Kent, Canterbury, United Kingdom., Yang F, Di Nicolantonio F; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy., Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy., Arena S; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Voest EE; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Bardelli A; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Garnett MJ; Wellcome Sanger Institute, Cambridge, United Kingdom. mg12@sanger.ac.uk.

مؤلفون مشاركون: Cell Model Network UK Group

المصدر: Cancer discovery [Cancer Discov] 2021 Aug; Vol. 11 (8), pp. 1923-1937. Date of Electronic Publication: 2021 Apr 09.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

مواضيع طبية MeSH: DNA Mismatch Repair*, Colorectal Neoplasms/*therapy , Werner Syndrome Helicase/*genetics, Colorectal Neoplasms/genetics ; Drug Therapy ; Humans ; Immunotherapy ; Molecular Targeted Therapy

المؤلفون: Ooft SN; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Weeber F; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Schipper L; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Dijkstra KK; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., McLean CM; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Kaing S; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., van de Haar J; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Prevoo W; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Snaebjornsson P; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoes LR; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands., Chalabi M; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Velden D; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center AMC, Amsterdam, The Netherlands., van Leerdam M; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Boot H; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Grootscholten C; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands., Bloemendal HJ; Department of Internal Medicine/Oncology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands., Cuppen E; Oncode Institute, Utrecht, The Netherlands; Division of Biomedical Genetics, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands; Hartwig Medical Foundation, Amsterdam, The Netherlands., Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands; Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: E.voest@nki.nl.

المصدر: ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100103. Date of Electronic Publication: 2021 Apr 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

مواضيع طبية MeSH: Colorectal Neoplasms*/drug therapy , Pharmaceutical Preparations*, Humans ; Organoids ; Precision Medicine ; Prospective Studies

المؤلفون: Dijkstra KK; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Weeber F; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., Velds A; Central Genomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands., Kaing S; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., Peters DDGC; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands., Tesselaar MET; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands.

المصدر: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Mar 11; Vol. 12, pp. 627819. Date of Electronic Publication: 2021 Mar 11 (Print Publication: 2021).

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Intestinal Neoplasms/*pathology , Neuroendocrine Tumors/*pathology , Organoids/*pathology , Pancreatic Neoplasms/*pathology , Stomach Neoplasms/*pathology, Cell Death/drug effects ; Cell Line, Tumor ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; DNA Mismatch Repair/drug effects ; Everolimus/pharmacology ; Everolimus/therapeutic use ; Gene Dosage ; Humans ; Intestinal Neoplasms/drug therapy ; Intestinal Neoplasms/genetics ; Ki-67 Antigen/metabolism ; Mutation/genetics ; Neuroendocrine Tumors/drug therapy ; Neuroendocrine Tumors/genetics ; Organoids/drug effects ; Organoids/metabolism ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/genetics ; Exome Sequencing

SCR Disease Name: Gastro-enteropancreatic neuroendocrine tumor

المؤلفون: Black JRM; Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK., Bailey C; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK., Przewrocka J; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK., Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK., Gandhi S; Francis Crick Institute, London, UK., Gamblin S; Francis Crick Institute, London, UK., Barrell S; Francis Crick Institute, London, UK., Swanton C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London NW1 1AT, UK; University College London Hospitals NHS Trust, London, UK. Electronic address: charles.swanton@crick.ac.uk.

المصدر: Lancet (London, England) [Lancet] 2020 Oct 24; Vol. 396 (10259), pp. 1329-1330.

نوع المنشور: Letter; Research Support, Non-U.S. Gov't; Comment

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19* , SARS-CoV-2*, Asymptomatic Infections ; COVID-19 Testing ; Humans ; United Kingdom/epidemiology

المؤلفون: Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Monkhorst K; Department of Pathology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands., Schipper LJ; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Hartemink KJ; Department of Surgery, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands., Smit EF; Department of Thoracic Oncology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands., Kaing S; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., de Groot R; Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Wolkers MC; Department of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, the Netherlands; Landsteiner Laboratory, Amsterdam University Medical Center, Location AMC, 1105 AZ Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Clevers H; Hubrecht Institute, University Medical Center Utrecht, 3584 CT Utrecht, the Netherlands; Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Cuppen E; Centre for Molecular Medicine, University Medical Centre Utrecht, 3584 CG Utrecht, the Netherlands; Hartwig Medical Foundation, 1098 XH Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Voest EE; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: e.voest@nki.nl.

المصدر: Cell reports [Cell Rep] 2020 May 05; Vol. 31 (5), pp. 107588.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE

مواضيع طبية MeSH: Precision Medicine*/methods, Carcinoma, Non-Small-Cell Lung/*pathology , Lung Neoplasms/*pathology , Organoids/*pathology, Humans ; Lung Neoplasms/genetics ; Mutation/genetics

المؤلفون: Black JRM; Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London, UK., Bailey C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Przewrocka J; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Dijkstra KK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; University College London Hospitals NHS Trust, London, UK. Electronic address: charles.swanton@crick.ac.uk.

المصدر: Lancet (London, England) [Lancet] 2020 May 02; Vol. 395 (10234), pp. 1418-1420. Date of Electronic Publication: 2020 Apr 16.

نوع المنشور: Letter

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Laboratory Techniques* , Coronavirus Infections*/diagnosis , Coronavirus Infections*/epidemiology , Coronavirus Infections*/prevention & control , Coronavirus Infections*/transmission , Health Personnel* , Mass Screening* , Pandemics*/prevention & control , Pneumonia, Viral*/diagnosis , Pneumonia, Viral*/epidemiology , Pneumonia, Viral*/prevention & control , Pneumonia, Viral*/transmission, Infectious Disease Transmission, Professional-to-Patient/*prevention & control, Asymptomatic Diseases ; Betacoronavirus ; COVID-19 ; COVID-19 Testing ; Cross Infection/prevention & control ; Health Workforce ; Humans ; Quarantine ; RNA, Viral/analysis ; Real-Time Polymerase Chain Reaction ; SARS-CoV-2 ; United Kingdom